Sesotho
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Lihlahisoa tsa lihlopha
Lihlahisoa tse hlahisitsoeng
Matlapa a Lenopril a Matlafatsang Taolo ea Khatello ea Mali le Bophelo bo Botle ba Pelo

Matlapa a Lenopril a Matlafatsang Taolo ea Khatello ea Mali le Bophelo bo Botle ba Pelo
Telmisartan Betere antihypertensive Ho sireletsa renal

Telmisartan Betere antihypertensive Ho sireletsa renal
Flumazenil Mohanyetsi oa Moamoheli oa GABAA ea Khethiloeng le Likopo tsa eona tsa Phekolo

Flumazenil Mohanyetsi oa Moamoheli oa GABAA ea Khethiloeng le Likopo tsa eona tsa Phekolo
Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers
Dabrafenib Phekolo e Lebisitsoeng bakeng sa Kankere ea BRAF-Mutated

Dabrafenib Phekolo e Lebisitsoeng bakeng sa Kankere ea BRAF-Mutated
Tirzepatide Dual GLP-1 le GIP Receptor Agonist bakeng sa Taolo ea Boima le Taolo ea Glycemic

Tirzepatide Dual GLP-1 le GIP Receptor Agonist bakeng sa Taolo ea Boima le Taolo ea Glycemic
Cisapride Gastric Stimulant bakeng sa Indigestion le Mathata a Ts'ila

Cisapride Gastric Stimulant bakeng sa Indigestion le Mathata a Ts'ila
YK-11 SARM e Matla bakeng sa Kaho ea mesifa, Matla a Matla, le Myostatin Inhibition

YK-11 SARM e Matla bakeng sa Kaho ea mesifa, Matla a Matla, le Myostatin Inhibition
Ostarine (MK-2866) SARM e fapaneng bakeng sa Khōlo ea Mesifa, Tahlehelo ea Mafura le 'Mele oa Recomposition

Ostarine (MK-2866) SARM e fapaneng bakeng sa Khōlo ea Mesifa, Tahlehelo ea Mafura le 'Mele oa Recomposition
MK-677 Motsoako o Ikhethileng oa Khōlo ea Mesifa, Mamello, le Pholiso

MK-677 Motsoako o Ikhethileng oa Khōlo ea Mesifa, Mamello, le Pholiso
0102030405
Tirzepatide Dual GLP-1 le GIP Receptor Agonist bakeng sa Taolo ea Boima le Taolo ea Glycemic
Tirzepatide Dual GLP-1 le GIP Receptor Agonist bakeng sa Taolo ea Boima le Taolo ea Glycemic
Tirzepatide Dual GLP-1 le GIP Receptor Agonist bakeng sa Taolo ea Boima le Taolo ea Glycemic
Tirzepatide Dual GLP-1 le GIP Receptor Agonist bakeng sa Taolo ea Boima le Taolo ea Glycemic

Tirzepatide Dual GLP-1 le GIP Receptor Agonist bakeng sa Taolo ea Boima le Taolo ea Glycemic

Theko ea litšupiso:USD 300-600/g

  • Lebitso la Sehlahiswa Tirzepatide
  • Nomoro ea CAS. 2023788-19-2
  • MF C225H348N48O68
  • MW 4813.45
Iteanye le rona
lintlha tsa sehlahisoa

Tlhaloso e Felletseng

Tirzepatide ke moriana o mocha o sebelisoang bakeng sa taolo ea boima ba nako e telele ho bakuli ba batenya ba nang le botenya ba batho ba baholo kapa mathata a amanang le boima ba 'mele. Ke agonist e itšetlehileng ka tsoekere ea glucagon polypeptide (GIP) le glucagon-like peptide-1 (GLP-1) receptors. E amohetsoe ke FDA ka 2022, tirzepatide e kopanya litlamorao tsa li-enteric proinsulins ho molek'hule e le 'ngoe, e matlafatsa secretion ea insulin le ho fokotsa maemo a glucagon. Sengoliloeng sena se hlahloba mokhoa oa ts'ebetso, katleho ea bongaka, le boemo ba polokeho ea tirzepatide e le pheko e tlatselletsang bakeng sa ho theola boima ba 'mele le taolo e ntlafalitsoeng ea glycemic ho bakuli ba nang le lefu la tsoekere la mofuta oa 2.

I. Ho utloisisa Tirzepatide:
A. Ke agonist e itšetlehileng ka Glucose ea li-receptor tsa GIP le GLP-1
B. Mokhoa oa ts'ebetso: ho ntlafatsa tlhahiso ea insulin ea mohato oa I le oa II, ho fokotsa maemo a glucagon.

II. Tšebeliso ea Kliniki le Tumello ea FDA:
A. Pontšo: Ho laola boima ba nako e telele ho bakuli ba batenya ba nang le botenya ba batho ba baholo kapa mafu a amanang le boima ba 'mele.
B. Phekolo e thusang bakeng sa ho ntlafatsa taolo ea glycemic ho batho ba baholo ba nang le lefu la tsoekere la mofuta oa 2
Tumello le papatso ea C. FDA ke Eli Lilly ka 2022

1715863859091roe

III. Katleho ho Taolo ea Boima:

A. Katleho ea papiso:

Peresente ea ho theola boima ba 'mele: Lethal dose le tlase (5mg), lethal dose e mahareng (10mg), le sehlopha se phahameng (15mg)

Karolelano ea liphesente tsa tahlehelo ea boima ba 'mele ka lihlopha tse fapaneng tsa litekanyetso

Papiso le sehlopha sa placebo

Peresente ea batho ba theolelang boima ba 'mele ho feta 20%

B. Boemo ba polokeho: Khafetsa ea maikutlo a mabe ha a bapisoa le sehlopha sa placebo

C. Papiso le meriana e meng ea ho theola boima ba 'mele:

Orlistat (over-the-counter): Phapang ea liphesente tsa tahlehelo ea boima ba 'mele


IV. Mokhoa oa Taolo ea Glycemic le Tahlehelo ea Boima:

A. Ho kenya tšebetsong li-receptor tsa GLP-1 le GIP

B. Khatello ea takatso ea lijo le ho fokotsa ho ja lijo



17158639023143ie


Tirzepatide, joalo ka GLP-1 le GIP receptor agonist, e fana ka taolo e sebetsang ea boima ba 'mele le taolo e ntlafalitsoeng ea glycemic ho bakuli ba batenya ba baholo ba nang le botenya kapa bokuli bo amanang le boima ba' mele, hammoho le ho batho ba nang le lefu la tsoekere la mofuta oa 2. Mokhoa oa eona oa ts'ebetso o itšetlehileng ka tsoekere o ntlafatsa secretion ea insulin mme o fokotsa maemo a glucagon. Ka liperesente tse kholo tsa tahlehelo ea boima ba 'mele le boemo bo botle ba polokeho, tirzepatide e hlahella e le moriana o matla bakeng sa taolo ea boima ba nako e telele. Lipatlisiso tse ling le lithuto tsa bongaka li tla tsoelapele ho hlahloba melemo le ts'ebeliso ea moriana ona o tšepisang.
Bakeng sa ho fana ka boiphihlelo bo betere ba khoebo, re ka etsa capsule le lihlahisoa tsa metsi, ho latela litlhoko tsa hau tsa lisebelisoa.
Re ka etsa litekanyetso tsa litekanyetso: 500mg/capsule, 550mg/capsule, 600mg/capsule.
Re ka etsa sephutheloana ka mokhoa o ikhethileng: 60 caps / botlolo, 90 caps / botlolo, 120 caps / botlolo.
Re ka etsa likhetla le mebala ea li-capsule: likhetla tsa li-capsule tsa semela, likhetla tsa likhetla tsa gelatin.

Tlhaloso

1715845381118yxs